Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | EYA2 | O00167 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658107 | 0.95 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL10283828 | 0.88 | TDP1 (0.44) | TDP1EYA2APPACEBLM | |
| SCHEMBL18100444 | 0.88 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| SCHEMBL18292047 | 0.88 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Trifluoroacetic Acid SCHEMBL5502459 | 0.87 | TDP1 (0.39) | TDP1EYA2APPACEBLM | |
| SCHEMBL24176993 | 0.86 | TDP1 (0.65) | TDP1EYA2APPACEBLM | |
| SCHEMBL10283576 | 0.84 | TDP1 (0.46) | TDP1EYA2APPACEBLM | |
| SCHEMBL9338981 | 0.84 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| SCHEMBL10170332 | 0.83 | TDP1 (0.39) | TDP1EYA2APPACEBLM | |
| Hydrochloric Acid SCHEMBL9340884 | 0.82 | TDP1 (0.48) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | THE ASAN FOUNDATION (KR) | 2023-05-11 | — | — | US | disclosed |
| US-10758634-B2 | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography | WAKE FOREST UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190038785-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS USING ZIRCONIUM-89 IN IMMUNO-POSITRON EMISSION TOMOGRAPHY | WAKE FOREST UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-20130251788-A1 | Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-09-26 | — | — | US | disclosed |
| US-8449979-B2 | Molecular aggregate capable of undergoing phase transition by dehydrating condensation and method of phase transition thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20090023003-A1 | Molecular Aggregate Capable of Undergoing Phase Transition by Dehydrating Condensation and Method of Phase Transition Thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758634-B2 | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography | PAICS, IKZF2, ZRANB2 | TDP1 1238/4885EYA2 4164/4885APP 3902/4885 |
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | SERPINC1, F3, F11 | TDP1 830/4885EYA2 4879/4885APP 2797/4885 |
| US-20190038785-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS USING ZIRCONIUM-89 IN IMMUNO-POSITRON EMISSION TOMOGRAPHY | PAICS, IKZF2, ZRANB2 | TDP1 1238/4885EYA2 4164/4885APP 3902/4885 |
| US-20130251788-A1 | Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle | VAPB, VAPA, NSF | TDP1 2116/4885EYA2 4008/4885APP 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.